Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 8/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.52 |
| ▸ | ITGAL | P20701 | 8/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145900 | 0.98 | ITGB2 (0.52) | ITGB2ICAM1ITGALHRH3SIGMAR1 | |
| SCHEMBL7144904 | 0.92 | ITGB2 (0.51) | ITGB2ICAM1ITGALHRH3MEN1 | |
| SCHEMBL7141580 | 0.90 | ITGAL (0.67) | ITGB2ICAM1ITGALHRH3SIGMAR1 | |
| SCHEMBL7141565 | 0.86 | ITGB2 (0.68) | ITGB2ICAM1ITGALTSHR | |
| SCHEMBL7143429 | 0.86 | ITGB2 (0.46) | ITGB2ICAM1ITGAL | |
| SCHEMBL7144872 | 0.81 | ITGB2 (0.44) | ITGB2ICAM1ITGALSIGMAR1MEN1 | |
| SCHEMBL7146694 | 0.77 | ITGB2 (0.66) | ITGB2ICAM1ITGALSIGMAR1 | |
| SCHEMBL7146813 | 0.77 | ITGB2 (0.51) | ITGB2ICAM1ITGALSIGMAR1ALDH1A1 | |
| SCHEMBL7147400 | 0.76 | ITGB2 (0.67) | ITGB2ICAM1ITGALSIGMAR1 | |
| SCHEMBL6199715 | 0.68 | ITGAL (0.57) | ITGB2ICAM1ITGALMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | claimed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | claimed |
| EP-1294685-A1 | ARYL PHENYCYCLOPROPYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE-SUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | disclosed |
| WO-2002002522-A1 | ARYL PHENYCYCLOPROPYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE-SUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICAM1, VCAM1, CD47 | ITGB2 120/4885ICAM1 1/4885ITGAL 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.